Editor’s Note
Daewoong Pharmaceutical has announced a strengthened distribution management system for its botulinum toxin product Nabota, aimed at preventing illegal distribution and ensuring patient safety. The company emphasizes the critical need for strict cold chain maintenance, deploying temperature-controlled containers and real-time monitoring to detect even minor deviations.
Daewoong Pharmaceutical (CEO: Park Sung-soo and Lee Chang-jae) announced that it has comprehensively strengthened its authentic distribution management system to prevent illegal distribution of its botulinum toxin product ‘Nabota’ and protect patient safety.
Botulinum toxin, a biological product, requires strict cold chain management at 2–8°C. Temperature deviations can lead to protein denaturation, reduced efficacy, and increased risk of side effects, making illegal distribution a critical threat to patient safety. Daewoong Pharmaceutical operates containers that maintain optimal temperature for up to 168 hours and a real-time monitoring system, immediately halting distribution if any deviation of even 0.1°C is detected.
Additionally, starting in January this year, the company introduced a policy of permanently terminating transactions upon detection of illegal distribution. Recently, it took immediate action to suspend transactions for domestic supply quantities where unauthorized removal was suspected. The company also explained that products flagged due to past FDA import refusal records are those distributed through unauthorized, abnormal channels.
However, due to limitations in corporate authority—such as the requirement to submit specific evidence when uncovering illegal pharmaceutical distribution—practical investigation and cooperation from government authorities are essential.
